Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR 1,580.00
+3.70 (0.23%)
Jul 31, 2026, 3:30 PM IST
Aurobindo Pharma Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Aurobindo Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,571. The average 1-year stock price forecast is 0.58% lower than the current stock price, while the lowest is ₹1,185 (-25.00%) and the highest is ₹1,810 (+14.56%).
Price Target: ₹1,571 (-0.58%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Feb 15, 2026.
Analyst Ratings
The average analyst rating for Aurobindo Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 14 | 15 | 13 | 13 | 13 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 1 | 1 | 5 | 5 | 5 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 2 | 2 | 2 | 2 | 2 |
| Total | 26 | 25 | 26 | 28 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst ICICI Securities No rating | ICICI Securities | Buy Maintains ₹1,425 | Buy | Maintains | ₹1,425 | -9.81% | Feb 15, 2026 |
Unknown Analyst Axis Direct No rating | Axis Direct | Buy Maintains ₹1,345 | Buy | Maintains | ₹1,345 | -14.87% | Feb 11, 2026 |
Financial Forecast
Revenue This Year
395.05B
from 336.53B
Increased by 17.39%
Revenue Next Year
436.11B
from 395.05B
Increased by 10.39%
EPS This Year
77.60
from 61.11
Increased by 26.98%
EPS Next Year
90.36
from 77.60
Increased by 16.44%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.